Panelists:
Jenny Hamilton, PhD
Postdoc, Doudna Lab
UC Berkeley
Mark Kay, MD, PhD
Professor of Pediatrics and Genetics
Stanford Medicine
Michael Mitchell, PhD
Associate Professor of Bioengineering
UPenn
- Time:
The excitement surrounding advances in genomic medicine is palpable; it feels like the field may be at a tipping point. There were five gene therapy approvals in the past five years, but five approvals may come in 2023 alone. And the FDA aims to approve 10–20 new cell and gene therapies per year by 2025. But there are hurdles that still need clearing. Arguably, the biggest hurdle is delivery of genetic payloads to target cells. Indeed, multiple CRISPR pioneers have shifted their focus from genome editing to tackling the delivery problem.
On this episode of GEN Live, we’ll talk to three experts in delivery—each with their own expertise in delivery. Mark Kay, MD, PhD, Michael Mitchell, PhD, and Jenny Hamilton, PhD, will discuss the advantages and challenges associated with different delivery methods: adeno-associated viruses (AAVs), lipid nanoparticles (LNPs) and other, emerging mechanisms in development. At the end of the hour-long discussion, we will have a deeper understanding of the roadblocks that stand in the way of delivery, and perhaps a better idea of how to solve them.
A live Q&A session followed the discussion, offering a chance to pose questions to our expert panelists.
Produced with support from:
